LL-37

Why I considered it

LL-37 is commonly described as an antimicrobial, immune-support, and healing peptide. Because it participates in inflammation, immune-cell recruitment, angiogenesis, and wound closure, it is easy to extend that biology into a broader claim about recovery or resilience.

What problem it may actually solve

LL-37 is released locally by immune and epithelial cells around infection and tissue damage. The human treatment research has mainly applied synthetic LL-37 directly to chronic skin ulcers. That is a targeted attempt to supplement a wound environment that is not progressing normally, not an attempt to make an otherwise healthy body better at recovery.

Why I passed

I do not have a chronic wound to treat. I found no controlled human evidence that systemic LL-37 improves muscle recovery, tendon or ligament repair, training adaptation, immune resilience, or future healing capacity. Its activity is temporary and context-dependent; the research does not show a durable biological upgrade after exposure ends.

The route mismatch

A topical pharmaceutical formulation placed directly on an ulcer is not evidence for subcutaneous use elsewhere in the body. Local concentration and tissue context are part of the intervention. I found no validated subcutaneous regimen, systemic pharmacokinetic model, or measurable healthy-person endpoint that would make an injectable N=1 experiment interpretable.

What could reopen the decision

A specific wound-healing problem and credible route-matched clinical evidence could create a different decision. Human studies showing a repeatable systemic recovery or tissue-repair benefit would also change the question. The current endogenous mechanism and topical ulcer data do not establish either use.

What it is

LL-37 is the 37-amino-acid active fragment of the human cathelicidin precursor hCAP18. Neutrophils, epithelial cells, and other immune cells produce it as part of the local response to microbes and tissue damage. It can disrupt microbial membranes, but it also signals to host cells involved in inflammation, immune recruitment, blood-vessel formation, and wound closure.

The first wound signal

A 34-person randomized trial applied LL-37 topically to hard-to-heal venous leg ulcers twice weekly for four weeks. The 0.5 mg/mL group showed a stronger early healing signal than placebo, the 1.6 mg/mL result was weaker, and 3.2 mg/mL did not help. The nonlinear result also shows why more exposure cannot be assumed to produce more healing.

The larger trial

The follow-up Phase IIb trial analyzed 148 people receiving topical 0.5 mg/mL, 1.6 mg/mL, or placebo for 13 weeks. Estimated complete closure was 26.5%, 24.7%, and 25.3%, respectively, with no significant benefit in the full population. A favorable signal appeared only in a post-hoc subgroup with large ulcers, which remains a hypothesis for another adequately powered study.

Diabetic foot-ulcer evidence

A separate 25-person randomized trial found a better granulation index with topical 0.5 mg/mL cream over four weeks. Wound-area reduction, inflammatory markers, and bacterial colonization were not significantly better than placebo. That small local study does not establish a general antimicrobial or recovery effect.

Why endogenous does not mean harmless

LL-37 is a broad immune signal rather than a single-purpose repair switch. Experimental work shows that it can activate mast cells and platelets and can carry self-DNA into immune cells, a pathway involved in psoriasis. FDA states that compounded LL-37 raises potential immunogenicity and peptide-characterization concerns and that the available human safety information is insufficient. Those signals do not prove that a short exposure causes harm, but they remove the basis for assuming that an unneeded systemic experiment is benign.

Sources

• Lee et al., Biochimica et Biophysica Acta, 2015 — LL-37 structure, antimicrobial activity, and host-cell signaling.
• Grönberg et al., Wound Repair and Regeneration, 2014 — first-in-human randomized venous leg-ulcer trial.
• Mahlapuu et al., Wound Repair and Regeneration, 2021 — 148-person Phase IIb venous leg-ulcer trial.
• Miranda et al., Archives of Dermatological Research, 2023 — small randomized diabetic foot-ulcer cream trial.
• Lande et al., Nature, 2007 — LL-37, self-DNA transport, and innate immune activation in psoriasis.
• Salamah et al., Blood Advances, 2018 — platelet activation and thrombus formation in experimental systems.
• FDA compounding safety-risk summary — current LL-37 safety-information and product-characterization concerns.